228 related articles for article (PubMed ID: 37563692)
1. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Ouji N; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
J Exp Clin Cancer Res; 2023 Aug; 42(1):205. PubMed ID: 37563692
[TBL] [Abstract][Full Text] [Related]
2. CRISPR-Cas9-Mediated TIM3 Knockout in Human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells.
Morimoto T; Nakazawa T; Matsuda R; Nishimura F; Nakamura M; Yamada S; Nakagawa I; Park YS; Tsujimura T; Nakase H
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800561
[TBL] [Abstract][Full Text] [Related]
3. An efficient feeder-free and chemically-defined expansion strategy for highly purified natural killer cells derived from human cord blood.
Nakazawa T; Maeoka R; Morimoto T; Matsuda R; Nakamura M; Nishimura F; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
Regen Ther; 2023 Dec; 24():32-42. PubMed ID: 37303464
[TBL] [Abstract][Full Text] [Related]
4. Antitumor Effects of Intravenous Natural Killer Cell Infusion in an Orthotopic Glioblastoma Xenograft Murine Model and Gene Expression Profile Analysis.
Morimoto T; Nakazawa T; Matsuda R; Maeoka R; Nishimura F; Nakamura M; Yamada S; Park YS; Tsujimura T; Nakagawa I
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397112
[TBL] [Abstract][Full Text] [Related]
5.
Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
[TBL] [Abstract][Full Text] [Related]
6. Bulk RNA sequencing reveals the comprehensive genetic characteristics of human cord blood-derived natural killer cells.
Morimoto T; Nakazawa T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Yamada S; Nakagawa I; Park YS; Tsujimura T
Regen Ther; 2024 Mar; 25():367-376. PubMed ID: 38405180
[TBL] [Abstract][Full Text] [Related]
7. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
[TBL] [Abstract][Full Text] [Related]
8. Genome Editing Reveals Glioblastoma Addiction to MicroRNA-10b.
El Fatimy R; Subramanian S; Uhlmann EJ; Krichevsky AM
Mol Ther; 2017 Feb; 25(2):368-378. PubMed ID: 28153089
[TBL] [Abstract][Full Text] [Related]
9. Applications of CRISPR-Cas9 Technology to Genome Editing in Glioblastoma Multiforme.
Al-Sammarraie N; Ray SK
Cells; 2021 Sep; 10(9):. PubMed ID: 34571991
[TBL] [Abstract][Full Text] [Related]
10. Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells.
Gurney M; O'Reilly E; Corcoran S; Brophy S; Krawczyk J; Otto NM; Hermanson DL; Childs RW; Szegezdi E; O'Dwyer ME
Cytotherapy; 2022 Nov; 24(11):1087-1094. PubMed ID: 36050244
[TBL] [Abstract][Full Text] [Related]
11. Ex Vivo Expansion and CRISPR-Cas9 Genome Editing of Primary Human Natural Killer Cells.
Huang RS; Lai MC; Lin S
Curr Protoc; 2021 Sep; 1(9):e246. PubMed ID: 34529358
[TBL] [Abstract][Full Text] [Related]
12. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
[TBL] [Abstract][Full Text] [Related]
13. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
[TBL] [Abstract][Full Text] [Related]
14. Gene Therapy for Drug-Resistant Glioblastoma via Lipid-Polymer Hybrid Nanoparticles Combined with Focused Ultrasound.
Yang Q; Zhou Y; Chen J; Huang N; Wang Z; Cheng Y
Int J Nanomedicine; 2021; 16():185-199. PubMed ID: 33447034
[TBL] [Abstract][Full Text] [Related]
15. Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity.
Bernard PL; Delconte R; Pastor S; Laletin V; Costa Da Silva C; Goubard A; Josselin E; Castellano R; Krug A; Vernerey J; Devillier R; Olive D; Verhoeyen E; Vivier E; Huntington ND; Nunes J; Guittard G
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35589278
[TBL] [Abstract][Full Text] [Related]
16. Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins.
Huang RS; Shih HA; Lai MC; Chang YJ; Lin S
Front Immunol; 2020; 11():1008. PubMed ID: 32528479
[TBL] [Abstract][Full Text] [Related]
17. Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells.
Shaim H; Shanley M; Basar R; Daher M; Gumin J; Zamler DB; Uprety N; Wang F; Huang Y; Gabrusiewicz K; Miao Q; Dou J; Alsuliman A; Kerbauy LN; Acharya S; Mohanty V; Mendt M; Li S; Lu J; Wei J; Fowlkes NW; Gokdemir E; Ensley EL; Kaplan M; Kassab C; Li L; Ozcan G; Banerjee PP; Shen Y; Gilbert AL; Jones CM; Bdiwi M; Nunez-Cortes AK; Liu E; Yu J; Imahashi N; Muniz-Feliciano L; Li Y; Hu J; Draetta G; Marin D; Yu D; Mielke S; Eyrich M; Champlin RE; Chen K; Lang FF; Shpall EJ; Heimberger AB; Rezvani K
J Clin Invest; 2021 Jul; 131(14):. PubMed ID: 34138753
[TBL] [Abstract][Full Text] [Related]
18. Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain.
Lee SJ; Kang WY; Yoon Y; Jin JY; Song HJ; Her JH; Kang SM; Hwang YK; Kang KJ; Joo KM; Nam DH
BMC Cancer; 2015 Dec; 15():1011. PubMed ID: 26704632
[TBL] [Abstract][Full Text] [Related]
19. High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.
Clara JA; Levy ER; Reger R; Barisic S; Chen L; Cherkasova E; Chakraborty M; Allan DSJ; Childs R
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35135865
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]